Developer docs
API playgroundTry for free, no card

Search company profiles

Lavipharm Labs

Full company profile

uuid000eduf

Namestring
Lavipharm Labs
Legal namestring
Lavipharm SA
Websiteurl
lavipharm.gr
Company typeenum
Public
Founded yearint
1911
Descriptiontext

Lavipharm Labs is a Greek pharmaceutical company (legal entity Lavipharm SA) listed on the Athens Stock Exchange under ticker LAVI and headquartered in Athens, Greece. Founded in 1911, the company operates in the outpatient pharmaceutical segment with a stated focus on topical and transdermal drug delivery solutions, targeting healthcare providers and outpatients requiring pain management therapies.

The company's core product is Durogesic, a transdermal fentanyl patch for pain management, distributed and sold internationally under a licensing agreement with Janssen/Johnson & Johnson. This Durogesic agreement is positioned as the central lever of Lavipharm's international growth strategy, while product acquisitions and geographic diversification are projected as additional growth drivers. Beyond Durogesic, the portfolio approach emphasizes specialty outpatient pharmaceuticals; historical inorganic moves include the October 2000 acquisition of Separex for an undisclosed amount.

Lavipharm generates revenue primarily through pharmaceutical product sales spanning its domestic Greek market and international markets reached via the Durogesic agreement. In 2025 the company reported €70 million in consolidated sales (up 14.8% YoY), adjusted EBITDA of €15.4 million (up 49%), and net profits of €5.99 million. Outpatient market share rose from 0.7% in 2021 to 1.2% in 2025, signaling sustained share gain against a small base. Distribution is conducted through pharmacy networks and healthcare providers, with the company pursuing an enterprise field sales go-to-market focused on international market entry.

Short descriptiontext

Lavipharm Labs is a Greek pharmaceutical company listed on the Athens Stock Exchange that develops and distributes outpatient specialty medicines, anchored by the Durogesic transdermal fentanyl patch licensed from Janssen/Johnson & Johnson, serving prescribers and outpatients in Greece and select international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical products, transdermal drug delivery, pain management drugs, outpatient medications, topical therapeutics
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Lavipharm generates revenue through the sale of pharmaceutical products including Durogesic (fentanyl patch). The company reported consolidated sales of 70 million euros in 2025, representing 14.8% growth year-over-year. Revenue is derived from both domestic Greek market and international expansion into new markets.

capital.gr
Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lavipharm Labs is a Greek pharmaceutical company that develops, distributes, and sells pharmaceutical products with a focus on topical and transdermal drug delivery solutions for the outpatient segment. Its portfolio is anchored by Durogesic (transdermal fentanyl patches), distributed internationally under a licensing agreement, and the company pursues growth through product acquisitions and geographic diversification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Market share increased from 0.7% to 1.2% in outpatient market (2021-2025)
+2 more records
Product overview1 text field

Lavipharm Labs is a Greek pharmaceutical company operating in the outpatient segment with a focus on topical and transdermal drug delivery solutions. The company operates with a portfolio strategy centered on Durogesic (transdermal fentanyl patches) as a key revenue driver, complemented by product acquisitions and geographic diversification efforts. The company increased its outpatient market share from 0.7% in 2021 to 1.2% in 2025, and projects future growth from new product acquisitions and international market expansion.

Product and service1 record
1Durogesic
CategoryPain Management Pharmaceuticals
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Greek pharmaceutical company with a comparable branded generics/specialty portfolio and outpatient market presence in Greece, making it a direct domestic peer for Lavipharm.

TypeDirect peer
Description

Athens-based pharmaceutical manufacturer with overlapping branded and specialty product offerings, serving similar outpatient channels and competing for the same Greek market share.

TypeDirect peer
Description

Established Greek pharmaceutical firm operating across branded and specialty therapeutics, comparable in scale and channel mix to Lavipharm in the domestic outpatient segment.

4Specifar Pharmaceuticals
TypeDirect peer
Description

Greek-focused pharmaceutical company with a similar generics and specialty portfolio, competing in the same outpatient channels and therapeutic categories as Lavipharm.

5Mundipharma
TypeBroad incumbent
Description

Global specialty pharmaceutical company with a strong focus on pain management, making it a comparable incumbent in the same therapeutic category where Lavipharm's Durogesic operates.

TypeBroad incumbent
Description

European pain-specialist pharmaceutical company with branded therapies and licensing/in-licensing models analogous to Lavipharm's Durogesic arrangement with J&J.

TypeBroad incumbent
Description

Large specialty/generics pharmaceutical company with European distribution scale and outpatient product breadth, comparable to Lavipharm as a broad pharma competitor in overlapping therapeutic categories.

TypeBroad incumbent
Description

Global pharmaceutical company with a large specialty and generics portfolio including pain therapies, representing a broad incumbent competing for the same outpatient prescription volumes Lavipharm targets.

TypeBroad incumbent
Description

European-focused specialty and generics pharmaceutical company with comparable mid-size scale and a similar strategy of branded/specialty product acquisitions in regional markets.

TypeBroad incumbent
Description

European specialty pharmaceutical company focused on dermatology and pain, comparable to Lavipharm as a mid-size European pharma with branded specialty products and international ambitions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lavipharm Labs

Pharmaceuticalslavipharm.gr

Lavipharm Labs is a Greek pharmaceutical company listed on the Athens Stock Exchange that develops and distributes outpatient specialty medicines, anchored by the Durogesic transdermal fentanyl patch licensed from Janssen/Johnson & Johnson, serving prescribers and outpatients in Greece and select international markets.

What Lavipharm Labs does

Lavipharm Labs is a Greek pharmaceutical company (legal entity Lavipharm SA) listed on the Athens Stock Exchange under ticker LAVI and headquartered in Athens, Greece. Founded in 1911, the company operates in the outpatient pharmaceutical segment with a stated focus on topical and transdermal drug delivery solutions, targeting healthcare providers and outpatients requiring pain management therapies.

The company's core product is Durogesic, a transdermal fentanyl patch for pain management, distributed and sold internationally under a licensing agreement with Janssen/Johnson & Johnson. This Durogesic agreement is positioned as the central lever of Lavipharm's international growth strategy, while product acquisitions and geographic diversification are projected as additional growth drivers. Beyond Durogesic, the portfolio approach emphasizes specialty outpatient pharmaceuticals; historical inorganic moves include the October 2000 acquisition of Separex for an undisclosed amount.

Lavipharm generates revenue primarily through pharmaceutical product sales spanning its domestic Greek market and international markets reached via the Durogesic agreement. In 2025 the company reported €70 million in consolidated sales (up 14.8% YoY), adjusted EBITDA of €15.4 million (up 49%), and net profits of €5.99 million. Outpatient market share rose from 0.7% in 2021 to 1.2% in 2025, signaling sustained share gain against a small base. Distribution is conducted through pharmacy networks and healthcare providers, with the company pursuing an enterprise field sales go-to-market focused on international market entry.

Lavipharm Labs firmographics

Firmographics
Name
Lavipharm Labs
Legal name
Lavipharm SA
Website
https://lavipharm.gr
Company type
Public
Founded year
1911
Operating status
Operating
Headcount range
101–250 employees
Short description
Lavipharm Labs is a Greek pharmaceutical company listed on the Athens Stock Exchange that develops and distributes outpatient specialty medicines, anchored by the Durogesic transdermal fentanyl patch licensed from Janssen/Johnson & Johnson, serving prescribers and outpatients in Greece and select international markets.
Ownership category
akta.pro rank

Lavipharm Labs industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical products
  • Transdermal drug delivery
  • Pain management drugs
  • Outpatient medications
  • Topical therapeutics

Where Lavipharm Labs is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Markets served

Lavipharm Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: Lavipharm generates revenue through the sale of pharmaceutical products including Durogesic (fentanyl patch). The company reported consolidated sales of 70 million euros in 2025, representing 14.8% growth year-over-year. Revenue is derived from both domestic Greek market and international expansion into new markets.

Go-to-market motion1 record

Lavipharm Labs product offering

Product offering

Core offering

Lavipharm Labs is a Greek pharmaceutical company that develops, distributes, and sells pharmaceutical products with a focus on topical and transdermal drug delivery solutions for the outpatient segment. Its portfolio is anchored by Durogesic (transdermal fentanyl patches), distributed internationally under a licensing agreement, and the company pursues growth through product acquisitions and geographic diversification.

Product overview

Lavipharm Labs is a Greek pharmaceutical company operating in the outpatient segment with a focus on topical and transdermal drug delivery solutions. The company operates with a portfolio strategy centered on Durogesic (transdermal fentanyl patches) as a key revenue driver, complemented by product acquisitions and geographic diversification efforts. The company increased its outpatient market share from 0.7% in 2021 to 1.2% in 2025, and projects future growth from new product acquisitions and international market expansion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Durogesic

Quantifiable outcome

  • Market share increased from 0.7% to 1.2% in outpatient market (2021-2025)
  • +2 more outcomes

Companies that use Lavipharm Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Lavipharm Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lavipharm Labs partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves4 records

Expansion highlights3 records

Lavipharm Labs competitors and assessment

Company assessment

Direct peers

  • ELPEN Pharmaceutical: Greek pharmaceutical company with a comparable branded generics/specialty portfolio and outpatient market presence in Greece, making it a direct domestic peer for Lavipharm.
  • Demo Pharmaceuticals: Athens-based pharmaceutical manufacturer with overlapping branded and specialty product offerings, serving similar outpatient channels and competing for the same Greek market share.
  • Vianex: Established Greek pharmaceutical firm operating across branded and specialty therapeutics, comparable in scale and channel mix to Lavipharm in the domestic outpatient segment.
  • Specifar Pharmaceuticals: Greek-focused pharmaceutical company with a similar generics and specialty portfolio, competing in the same outpatient channels and therapeutic categories as Lavipharm.

Broad incumbents

  • Mundipharma: Global specialty pharmaceutical company with a strong focus on pain management, making it a comparable incumbent in the same therapeutic category where Lavipharm's Durogesic operates.
  • Grünenthal: European pain-specialist pharmaceutical company with branded therapies and licensing/in-licensing models analogous to Lavipharm's Durogesic arrangement with J&J.
  • Teva Pharmaceutical Industries: Large specialty/generics pharmaceutical company with European distribution scale and outpatient product breadth, comparable to Lavipharm as a broad pharma competitor in overlapping therapeutic categories.
  • Viatris: Global pharmaceutical company with a large specialty and generics portfolio including pain therapies, representing a broad incumbent competing for the same outpatient prescription volumes Lavipharm targets.
  • Stada Arzneimittel: European-focused specialty and generics pharmaceutical company with comparable mid-size scale and a similar strategy of branded/specialty product acquisitions in regional markets.
  • Almirall: European specialty pharmaceutical company focused on dermatology and pain, comparable to Lavipharm as a mid-size European pharma with branded specialty products and international ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Lavipharm Labs social profiles

Digital presence

Lavipharm Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lavipharm Labs leadership team

Management profile

Number of profiles

Profiles1 record

Lavipharm Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lavipharm Labs M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lavipharm Labs

What does Lavipharm Labs do?

Lavipharm Labs is a Greek pharmaceutical company that develops, distributes, and sells pharmaceutical products with a focus on topical and transdermal drug delivery solutions for the outpatient segment. Its portfolio is anchored by Durogesic (transdermal fentanyl patches), distributed internationally under a licensing agreement, and the company pursues growth through product acquisitions and geographic diversification.

Is Lavipharm Labs a public or private company?

Lavipharm Labs is a public company. It is classified as public and is currently operating.

When was Lavipharm Labs founded?

Lavipharm Labs was founded in 1911. It employs 101 to 250 people.

Where is Lavipharm Labs based?

Lavipharm Labs is headquartered in Athens, Greece, in the Europe region.

How does Lavipharm Labs make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Lavipharm Labs's main competitors?

Direct peers on record are ELPEN Pharmaceutical, Demo Pharmaceuticals, Vianex and Specifar Pharmaceuticals. Broad incumbents are Mundipharma, Grünenthal, Teva Pharmaceutical Industries, Viatris, Stada Arzneimittel and Almirall.

Does Lavipharm Labs have an API?

No public API is recorded for Lavipharm Labs.

What industry is Lavipharm Labs in?

Lavipharm Labs's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals